NLS Pharma Business

Bavarian Nordic has upgraded its financial guidance for 2026, now expecting total revenue of approximately DKK 5,700 million and an EBITDA margin of around 30 percent, on the back of continued strength in its Public Preparedness business. The Danish vaccine maker is also launching a new share buyback programme of up to DKK 750 million.

The company has announced confidential submission of draft registration statement to the SEC to allow for a potential listing of ADSs in the United States.

Pixelgen Technologies has closed an oversubscribed USD 15.5 million Series B financing to accelerate global commercialization of its Proxiome Kit and expand the company’s presence in key markets.

The company reported a 16% increase in revenue at constant exchange rates in the first six months of 2026, driven mainly by continued growth in Vyepti and Rexulti.

SynAct Pharma has signed a term sheet with Brazilian pharmaceutical company Hipolabor to co-develop and commercialize resomelagon for dengue and other viral infections in Brazil.

Hansa Biopharma has announced that the first commercial patient in Australia has received a living donor kidney transplant following treatment with Idefirix (imlifidase), consistent with the indication approved by the Therapeutic Goods Administration (TGA).